中国新药杂志

阿比多尔抗病毒治疗研究进展

PDF下载

曹迪

中国新药杂志 | 综述 2021,30(8): 718-722

收起

中国新药杂志 |综述 2021 , 30 (8) : 718 -722

阿比多尔抗病毒治疗研究进展

全屏

[Author(id=1322245659835609501, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322245659055468950, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=94006719@qq.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322245659940467103, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322245659055468950, authorId=1322245659835609501, language=EN, stringName=Di CAO, firstName=Di, middleName=null, lastName=CAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmacy, the Third People's Hospital of Bengbu, Bengbu 233000, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322245660011770272, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322245659055468950, authorId=1322245659835609501, language=CN, stringName=曹迪, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=安徽省蚌埠市第三人民医院药学部，蚌埠　233000, bio={"content":"

曹迪，男，学士，副主任药师，主要从事临床药学工作。E-mail：94006719@qq.com。

"}, bioImg=null, bioContent=

曹迪，男，学士，副主任药师，主要从事临床药学工作。E-mail：94006719@qq.com。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322245659701391769, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322245659055468950, xref=null, ext=[AuthorCompanyExt(id=1322245659709780378, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322245659055468950, companyId=1322245659701391769, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmacy, the Third People's Hospital of Bengbu, Bengbu 233000, China), AuthorCompanyExt(id=1322245659730751899, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322245659055468950, companyId=1322245659701391769, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=安徽省蚌埠市第三人民医院药学部，蚌埠　233000)])])]

曹迪

作者信息

安徽省蚌埠市第三人民医院药学部，蚌埠　233000

作者简介:

曹迪，男，学士，副主任药师，主要从事临床药学工作。E-mail：94006719@qq.com。

Progress in researches on arbidol in anti-vital treatments

Di CAO

Affiliations

Department of Pharmacy, the Third People's Hospital of Bengbu, Bengbu 233000, China

出版时间: 2021-04-30

文章导航

摘要

收起

目前世界各国人民都受到新型冠状病毒（SARS-CoV-2）感染的威胁，体外研究和临床治疗中观察到阿比多尔（arbidol，ARB）有抗SARS-CoV-2活性，使其备受关注。阿比多尔是由前苏联研发的一种小分子吲哚衍生物，被批准用于甲型/乙型流感的防治。近年来的研究发现阿比多尔对多种病毒都有抗病毒活性，因其独特的抗病毒作用机制，为抗病毒治疗提供了新的突破口。为此，本文对阿比多尔的抗病毒研究进展做一综述，希望为进一步的临床研究提供参考。

关键词

阿比多尔 / 抗病毒治疗 / 研究进展 / 新型冠状病毒

Abstract

收起

At present, the pneumonia caused by the novel coronavirus (2019-nCoV) infection has developed into a serious public health problem. In vitro studies and clinical treatment have shown that arbidol has anti-2019-nCoV activity, which attracted much attention. Arbidol is a small molecule indole derivative developed by the former Soviet Union, which was approved for the prevention and control of Flu-A and Flu-B. Recent studies have found that arbidol has antiviral activity against a variety of viruses. Because of its unique antiviral effect, it provides a new breakthrough for antiviral therapy. For this reason, this article reviews the progress of antiviral research on arbidol.

Key words

arbidol / anti-vital treatment / progress in researches / SARS-CoV-2

引用本文

曹迪. 阿比多尔抗病毒治疗研究进展. 中国新药杂志, 2021 , 30 (8) : 718 -722 .

Di CAO. Progress in researches on arbidol in anti-vital treatments[J]. Chinese Journal of New Drugs, 2021 , 30 (8) : 718 -722 .

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

新型冠状病毒肺炎诊疗方案(试行第六版)[EB/OL]. (2020-03-06). https://doi.org/10.16505/j.2095-0136.2020.0016.

[2]

TROFIMOV FA, TSYSHKOVA NG, ZOTOVA SA, et al. Synthesis of a new antiviral agent, arbidole[J]. Pharm Chem J, 1993, 27(1): 75-76.

[3]

李曼, 李海伟, 梁烁斌, 等. 靶向流感病毒进入(细胞)抑制剂研究进展[J]. 中国科学: 化学, 2018, 48(11): 1347-1364.

[4]

BORISKIN YS, LENEVA IA, PÉCHEUR EI, et al. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion[J]. Curr Med Chem, 2008, 15(10): 997-1005.

[5]

BLAISING J, POLYAK SJ, PÉCHEUR EI. Arbidol as a broad-spectrum antiviral: an update[J]. Antiviral Res, 2014, 107: 84-94.

[6]

KADAM RU, WILSON IA. Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol[J]. Proc Natl Acad Sci USA, 2017, 114(2): 206-214.

[7]

FEDIAKINA IT, SHCHELKANOV MIU, DERIABIN PG, et al. Susceptibility of pandemic influenza virus A 2009 H1N1 and highly pathogenic avian influenza virus A H5N1 to antiinfluenza agents in cell culture[J]. Antibiot Chemoterapy, 2011, 56(3-4): 3-9.

[8]

LENEVA IA, SHUSTER AM. Antiviral etiotropic chemicals: efficacy against influenza A viruses A subtype H5N1[J]. Vopr Virusol, 2006, 51(5): 4-7.

[9]

FEDIAKINA IT, LENEVA IA, IAMNIKOVA SS, et al. Sensitivity of influenza A/H5 viruses isolated from wild birds on the territory of Russia to arbidol in the cultured MDCK cells[J]. Vopr Virusol, 2005, 50(6): 32-35.

[10]

LENEVA IA, FEDIAKINA IT, GUS'KOVA TA, et al. Sensitivity of various influenza virus strains to arbidol. Influence of arbidol combination with different antiviral drugs on reproduction of influenza virus A[J]. Ter Arkh, 2005, 77(8): 84-88.

[11]

ROMANOVSKAIA AA, DURYMANOV AM, SHARSHOV KA, et al. Investigation of susceptibility of influenza viruses A (H1N1), the cause of infection in humans in April-May 2009, to antivirals in MDCK cell culture[J]. Antibiot Khimioter, 2009, 54(5-6): 41-47.

[12]

LENEVA IA, FALYNSKOVA IN, MAKHMUDOVA NR, et al. Umifenovir susceptibility monitoring and characterization of influenza viruses isolated during ARBITR clinical study[J]. J Med Virol, 2019, 91(4): 588-597.

[13]

LIU Q, XIONG HR, LU L, et al. Antiviral and anti-inflammatory activity of arbidol hydrochloride in influenza A (H1N1) virus infection[J]. Acta Pharmacol Sin, 2013, 34(8): 1075-1083.

[14]

王玉亮, 王峰, 耿洁. 细胞因子与细胞因子风暴[EB/OL]. (2020-03-18). http://kns.cnki.net/kcms/detail/12.1116.R.20200311.1245.002.html.

[15]

杜小兵, 刘双, 温林芳, 等. 阿比多尔片治疗流行性感冒有效性和安全性的开放性临床试验研究[J]. 心肺血管病杂志, 2017, 36(7): 518-520.

[16]

BULGAKOVA VA, POROMOV AA, GREKOVA AI, et al. Pharmacoepidemiological study of the course of influenza and other acute respiratory viral infections in risk groups[J]. Ter Arkh, 2017, 89(1): 62-71.

[17]

PSHENICHNAYA NY, BULGAKOVA VA, LVOV NI, et al. Clinical efficacy of umifenovir in influenza and ARVI (study ARBITR)[J]. Ter Arkh, 2019, 91(3): 56-63.

[18]

陈致雯, 卢焯明. 阿比多尔颗粒治疗儿童流行性感冒疗效观察[J]. 现代中西医结合杂志, 2014, 23(14): 1528-1529.

[19]

MEO SA, ALHOWIKAN AM, AL-KHLAIWI T, et al. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV[J]. Eur Rev Med Pharmacol Sci, 2020, 24(4): 2012-2019.

[20]

WANG HL, YANG P, LIU KT, et al. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway[J]. Cell Res, 2008, 18(2): 290-301.

[21]

BLAISING J, LÉVY PL, POLYAK SJ, et al. Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking[J]. Antiviral Res, 2013, 100(1): 215-219.

[22]

纪晓光, 赵艳红, 张敏, 等. 阿比多尔抗SARS病毒的体外实验研究[J]. 解放军药学学报, 2004, 20(4): 274-276.

[23]

KHAMITOV RA, LOGINOVA SIA, SHCHUKINA VN, et al. Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures[J]. Vopr Virusol, 2008, 53(4): 9-13.

[24]

陈龙, 余修祥, 李旻, 等. 抗病毒药物甲磺酸阿比朵尔的合成[J]. 武汉工程大学学报, 2012, 34(8): 42-45.

[25]

AL-TAWFIQ JA, MEMISH ZA. Managing MERS-CoV in the healthcare setting[J]. Hosp Pract (1995), 2015, 43(3): 158-163.

[26]

关文达, 杜秋伶, 江海明, 等. 阿比多尔与连花清瘟胶囊对中东呼吸综合征冠状病毒的体内外抑制作用比较[J]. 广东医学, 2018, 39(23): 3454-3458.

[27]

WU CR, LIU Y, YANG YY, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods[EB/OL]. (2020-02-18). http://www.sciencedirect.com/science/article/pii/S2211383520302999.

[28]

李兰娟团队. 阿比朵尔、达芦那韦能有效抑制冠状病毒[EB/OL]. (2020-02-04) [2020-03-07]. https://www.chinanews.com/gn/2020/02-04/9078596.shtml.

[29]

XU KJ, CHEN YF, YUAN J, et al. Clinical efficacy of arbidol in patients with 2019 novel coronavirus-infected pneumonia: a retrospective cohort study[EB/OL]. (2020-02-25) [2020-03-07]. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3542148.

[30]

HAN WZ, QUAN B, GUO Y, et al. The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019[J]. J Med Virol, 2020, 92(5): 461-463.

[31]

HUANG C, WANG Y, LI X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223): 497-506.

[32]

瞿香坤, 郝树立, 马景贺, 等. 疏风解毒胶囊联合阿比多尔治疗新型冠状病毒肺炎的回顾性研究[EB/OL]. (2020-03-08). http://kns.cnki.net/kcms/detail/12.1108.r.20200225.1549.008.html.

[33]

张淑芹, 刘志屹, 张福明, 等. 盐酸阿比朵尔的抗柯萨奇B3病毒及免疫调节作用[J]. 中国地方病防治杂志, 2010, 25(5): 331-333.

[34]

张诗林, 吴迪, 薛枭, 等. 盐酸阿比朵尔抗柯萨奇B4病毒及免疫学机制的研究[J]. 中国地方病防治杂志, 2013, 28(5): 330-332.

[35]

ZHONG Q, YANG ZQ, LIU YY, et al. Antiviral activity of Arbidol against Coxsackie virus B5 in vitro and in vivo[J]. Arch Virol, 2009, 154(4): 601-607.

[36]

梁月玲, 张勇, 詹军, 等. 2017-2018年宁夏回族自治区手足口病流行特征及CV-A6基因特征分析[J]. 病毒学报, 2020, 36(2): 207-213.

[37]

刘静, 罗如平, 刘湘梅, 等. 盐酸阿比朵尔颗粒治疗手足口病效果观察[J]. 实用预防医学, 2012, 19(10): 1543-1544.

[38]

王鑫瑞, 张天锡, 王德民, 等. 治疗呼吸道合胞病毒的药物研究进展[J]. 中国实验方剂学杂志, 2020, 26(5): 241-250.

[39]

曹悦群, 孙乃玲. 盐酸阿比朵尔对呼吸道合胞病毒活性抑制作用[J]. 中国公共卫生, 2013, 29(12): 1838-1840.

[40]

孙慧, 杨占秋, 肖红, 等. 盐酸阿比朵尔抗呼吸道合胞病毒作用的实验研究[J]. 华西药学杂志, 2004, (6): 427-429.

[41]

BROOKS MJ, BURTSEVA EI, ELLERY PJ, et al. Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions[J]. J Med Virol, 2012, 84(1): 170-181.

[42]

石丽桥, 杨占秋, 何静, 等. 盐酸阿比朵尔抗腺病毒7型的实验研究[J]. 武汉大学学报(医学版), 2006, (1): 66-68.

[43]

SHI L, XIONG H, HE J, et al. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, Coxsackie virus and adenovirus in vitro and in vivo[J]. Arch Virol, 2007, 152(8): 1447-1455.

[44]

DENG HY, LUO F, SHI LQ, et al. Efficacy of arbidol on lethal hantaan virus infections in suckling mice and in vitro[J]. Acta Pharmacol Sin, 2009, 30(7): 1015-1024.

[45]

WEI F, LI JL, LING JX, et al. Establishment of SYBR green-based qPCR assay for rapid evaluation and quantification for anti-Hantaan virus compounds in vitro and in suckling mice[J]. Virus Genes, 2013, 46(1): 54-62.

[46]

HULSEBERG CE, FÉNÉANT L, SZYMAŃSKA-DE WIJS KM, et al. Arbidol and other low-molecular-weight drugs that inhibit Lassa and Ebola viruses[J]. J Virol, 2019, 93(8): e02185-18.

[47]

DELOGU I, PASTORINO B, BARONTI C, et al. In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant[J]. Antiviral Res, 2011, 90(3): 99-107.

[48]

DI MOLA A, PEDUTO A, LA GATTA A, et al. Structure-activity relationship study of arbidol derivatives as inhibitors of chikungunya virus replication[J]. Bioorg Med Chem, 2014, 22(21): 6014-6025.

[49]

PERFETTO B, FILOSA R, DE GREGORIO V, et al. In vitro antiviral and immunomodulatory activity of arbidol and structurally related derivatives in Herpes simplex virus type 1-infected human keratinocytes (HaCat)[J]. J Med Microbiol, 2014, 63(Pt 11): 1474-1483.

[50]

LI MK, LIU YY, WEI F, et al. Antiviral activity of arbidol hydrochloride against Herpes simplex virus I in vitro and in vivo[J]. Int J Antimicrob Agents, 2018, 51(1): 98-106.

[51]

MA N, SHEN MX, CHEN T, et al. Assessment of a new arbidol derivative against Herpes simplex virus II in human cervical epithelial cells and in BALB/c mice[J]. Biomed Pharmacother, 2019, 118: 109359.

[52]

DU Q, GU Z, LENEVA I, et al. The antiviral activity of arbidol hydrochloride against Herpes simplex virus type II (HSV-2) in a mouse model of vaginitis[J]. Int Immunopharmacol, 2019, 68: 58-67.

[53]

ZHAO CS, ZHAO YF, CHAI HF, et al. Synthesis and in vitro anti-hepatitis B virus activities of some ethyl 5-hydroxy-1H-indole-3-carboxylates[J]. Bioorg Med Chem, 2006, 14(8): 2552-2558.

[54]

CHAI H, ZHAO Y, ZHAO C, et al. Synthesis and in vitro anti-hepatitis B virus activities of some ethyl 6-bromo-5-hydroxy-1H-indole-3-carboxylates[J]. Bioorg Med Chem, 2006, 14(4): 911-917.

[55]

WEI XF, GAN CY, CUI J, et al. Identification of compounds targeting hepatitis B virus core protein dimerization through a split luciferase complementation assay[J]. Antimicrob Agents Chemother, 2018, 62(12): e01302-e01318.

[56]

PÉCHEUR EI, LAVILLETTE D, ALCARAS F, et al. Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol[J]. Biochemistry, 2007, 46(20): 6050-6059.

[57]

TEISSIER E, ZANDOMENEGHI G, LOQUET A, et al. Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug arbidol[J]. PLoS One, 2011, 6(1): e15874.

[58]

HEROD MR, ADEYEMI OO, WARD J, et al. The broad-spectrum antiviral drug arbidol inhibits foot-and-mouth disease virus genome replication[J]. J Gen Virol, 2019, 100(9): 1293-1302.

[59]

FINK SL, VOJTECH L, WAGONER J, et al. The antiviral drug arbidol inhibits Zika virus[J]. Sci Rep, 2018, 8(1): 8989.

2021年第30卷第8期

PDF下载

引用本文

BibTeX

文章信息

首发时间：2026-10-28
出版时间：2021-04-30

补充材料

相关文章

文章信息

作者

出版历史

录用日期：2020-07-22

基金

作者信息

安徽省蚌埠市第三人民医院药学部，蚌埠　233000

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322245659055468950

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT